The Nobel Laureate's Startup Just Bet Its Future on Your Cholesterol
Scribe Therapeutics just raised $155 million in its Nasdaq debut, betting that a single gene-editing injection can replace daily cholesterol pills forever. Co-founded by Nobel laureate Jennifer Doudna, the company is Wall Street's newest test of whether early-stage CRISPR platforms can still command serious money.
A $155 Million Gamble on a Single Shot
Imagine never taking a cholesterol pill again. Not because you gave up, but because a single injection rewired your liver to stop making the protein that drives your LDL sky-high. That's the pitch Scribe Therapeutics just brought to Wall Street, and investors bought it.
The Berkeley-born gene-editing company priced its IPO at $15 per share on Nasdaq (ticker: SCTX), landing at the top of its $13–$15 range. Underwriters exercised their full option to buy extra shares. Sanofi kicked in another $7.5 million through a private placement at the same price. Between the IPO, the overallotment, and the Sanofi placement, Scribe raised a total of roughly $155.5 million. For a company with exactly one drug candidate entering human trials, that's a remarkable vote of confidence.
But Scribe isn't just another CRISPR company. It's a test case for whether Wall Street will fund the next generation of gene editing, even when the science is still young.
Not Your Parents' CRISPR
Most people who've heard of CRISPR think of Cas9, the molecular scissors that won Jennifer Doudna and Emmanuelle Charpentier the Nobel Prize in 2020. Cas9 is powerful, but it has baggage: off-target cuts (editing DNA you didn't mean to), size constraints that make delivery tricky, and a crowded patent landscape.
Scribe took a different path. Instead of tweaking Cas9, co-founders Doudna, Benjamin Oakes, Brett Staahl, and David Savage built their platform around a rarer enzyme called CasX. Think of it as Cas9's smaller, more precise cousin. Their engineering team made over 125 changes to the natural CasX protein, boosting its cutting power by more than 100-fold while keeping off-target edits essentially undetectable.
The result is what Scribe calls its XE (X-Editor) platform. In monkeys, XE edited more than 75% of liver cells at a therapeutically relevant dose, with no detectable mistakes even when researchers cranked the dose to ten times above saturation. That's like a surgeon who gets more accurate the longer the operation goes, not less.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
CasX is also physically smaller than Cas9, which matters more than you'd think. A compact editor fits into more types of delivery vehicles (the biological "envelopes" that carry the editor to the right organ). That flexibility could eventually let Scribe target the liver, brain, eyes, heart, and muscle.
The Main Act: Silencing Cholesterol at the Source
Scribe's lead candidate, STX-1150, goes after PCSK9, a protein your liver makes that prevents your body from clearing LDL cholesterol from the blood. People born with naturally broken PCSK9 genes have dramatically lower LDL and up to 88% lower risk of coronary heart disease, with no apparent downside from a lifetime of low cholesterol.
Drug companies have been chasing PCSK9 for years. Antibody injections like Repatha and Praluent work, but patients need regular shots, typically once or twice a month. Scribe's proposition is bolder: one dose, potentially lasting years.
STX-1150 doesn't cut the PCSK9 gene. Instead, it uses Scribe's ELXR (Epigenetic Long-Term X-Repressor) technology to silence the gene, like flipping a dimmer switch rather than smashing the lightbulb. In monkeys, a single dose reduced LDL cholesterol by up to 68%. At a lower dose level, durable reductions of at least 50% lasted 18 months and counting.
The company has cleared regulatory hurdles to begin a Phase 1 trial in mid-2026, testing safety in people with high cholesterol and elevated cardiovascular risk. It's the moment where impressive animal data meets the unpredictability of human biology.
A Pipeline Built on Three Bad Lipids
PCSK9 is just the opening act. Behind STX-1150, Scribe has two more preclinical programs targeting other lipid villains:
STX-1200 goes after Lp(a) (pronounced "L-P-little-a"), a genetically determined risk factor that affects roughly one in five people and has no approved targeted treatment. In animal models, STX-1200 knocked down Lp(a) levels by more than 90%. The California Institute for Regenerative Medicine (CIRM) awarded Scribe a multi-year grant to push this candidate toward the clinic.
STX-1400 targets APOC3, a protein that drives triglyceride levels. High triglycerides can cause acute pancreatitis and contribute to heart disease. Scribe's data shows over 90% triglyceride reduction in preclinical models, with CIRM funding this program as well.
All three programs share Scribe's CasX backbone and liver-targeted lipid nanoparticle delivery. If the platform works for one target, scaling to the others becomes significantly easier.
Why Wall Street Cares (and Why It's Nervous)
Biotech IPOs have roared back in 2026. Through the first half of the year, 18 biotech companies went public, already surpassing all of 2025. First-quarter proceeds hit $1.7 billion, with a median deal size of roughly $287.5 million, the highest since the frothy days of 2021.
But this isn't 2021-style euphoria. Analysts describe a "bifurcated reopening" where investors eagerly fund later-stage companies with clinical data while remaining skeptical of early-stage platform stories. Scribe falls squarely in the second camp, and sector observers have explicitly called its filing "particularly notable" because of its early-stage pipeline.
The company's trump card is its founding team. Having a Nobel laureate as co-founder and scientific advisor carries weight, especially when the science involves a differentiated, non-Cas9 platform with strong preclinical numbers. Sanofi and Eli Lilly both expressed interest; Lilly's indication of interest was noted directly in the prospectus, and its shares wouldn't even be subject to the standard lock-up agreement.
The Elephant in the Room: Verve Is Already There
Scribe isn't the first company to chase one-and-done cholesterol editing. Verve Therapeutics has been at this for years, with its own PCSK9 program (VERVE-102) earning FDA Fast Track designation in April 2025. But there's a catch for anyone hoping to invest in Verve as a pure play: Eli Lilly acquired Verve in July 2025, folding it into Big Pharma's pipeline.
That acquisition arguably cleared space for Scribe. With Verve absorbed into Lilly, Scribe becomes the most prominent independent, publicly traded gene-editing company focused specifically on cardiometabolic disease. It's a niche, but the addressable market (hundreds of millions of people with high cholesterol worldwide) is anything but.
What Happens Next
Scribe's IPO is a bellwether. If the stock trades well, it signals that investors are willing to underwrite early-stage gene-editing platforms again, potentially opening the door for similar companies still waiting in the wings. If it struggles, it reinforces the message that even in a recovering market, the bar for pre-revenue CRISPR companies remains painfully high.
The real catalyst is the Phase 1 data for STX-1150, expected to begin reading out after dosing starts in mid-2026. That first look at human safety and cholesterol reduction will determine whether Scribe's elegant monkey data translates into something that could genuinely change how we treat heart disease.
For now, Scribe's fundraising buys it a shot at proving that the future of cholesterol management isn't a pill you take every day. It's a single injection you might never need again.
Clinical & Regulatory
4 min read
Two Biotech Siblings Just Fought Over the Family Business. Only One Won.
Two gene-editing companies born from the same Harvard lab just fought over who gets to treat a rare liver disease. The arbitration ruling has big implications for how the entire CRISPR ecosystem draws battle lines.
